noscript

News and Announcements

Sementis Ltd Announces New Developments

  • Published February 04, 2015 1:24PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Sementis has recently announced that over the past few months a number of “proof of concept” experiments have been successfully undertaken demonstrating the following:

1) The attenuated SCV is totally attenuated. That is, the data proves that the platform is non-replicating in mice which is one of the core aspects of the technology.

2) SCV vaccination protects mice from ECTV which is a mouse pox disease. This is the standard test for a vaccine to be considered a smallpox vaccine for humans.

3) Sementis’ Chikungunya vaccine-antigen design has been proven effective in protecting mice against Chikungunya infection – which has reached epidemic proportions in parts of the world.

4) Preliminary results from the peanut vaccine experiments are encouraging and consistent with a shift from an allergic TH2 to a TH1 response post-vaccination which is the primary objective.

Sementis’ Chairman, Maurice O’Shannassy commented,
“Needless to say, that with these results, we are extremely excited about the future and continue discussions with very interested potential global partners”.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now